Cost of Ongoing Trials. Except in the event of # termination by Licensee for an uncured material breach by Ovid, or # termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or # Ovid’s termination for Safety Reason, if there is any ongoing Clinical Trial of the Product under the Development Plan for which the Parties are sharing costs, then Licensee shall continue to share the cost of such Clinical Trial until the effective date of termination.

Ongoing Clinical Trials. If at the time of such termination, any Clinical Trials for the Product are being conducted by or on behalf of Ji Xing, its Affiliates or sublicensees, then, at [[Cytokinetics:Organization]]’ election on a trial-by-trial basis: # Ji Xing shall (and shall cause its Affiliates and sublicensees to) fully cooperate with [[Cytokinetics:Organization]] to transfer the conduct of all such Clinical Trials to [[Cytokinetics:Organization]], and [[Cytokinetics:Organization]] shall assume any and all liability and costs for such Clinical Trials after the effective date of such termination, provided that Ji Xing shall continue to bear all costs and expenses incurred in connection with the conduct of such Clinical Trials until the earlier of the completion of such Clinical Trial or ​ after the effective date of such termination; or # Ji Xing shall (and shall cause its Affiliates and sublicensees to) at its own cost and expense, orderly wind down in compliance with Applicable Laws the conduct of any such Clinical Trial which is not assumed by [[Cytokinetics:Organization]] under clause (i).

Ongoing Clinical Trials. As soon as practicable and subject to applicable law, including GCP, AstraZeneca shall transfer to FibroGen China the management and continued performance of all Clinical Trials for Products for the Territory ongoing as of the effective date of such termination that are being conducted by AstraZeneca at such time.

Cost of Ongoing Trials. Except in the event of # termination by Licensee for an uncured material breach by Ovid, or # termination by Licensee in the circumstances set forth in Section 14.2(b)(i) with respect to Ovid, or # Ovid’s termination for Safety Reason, if there is any ongoing Clinical Trial of the Product under the Development Plan for which the Parties are sharing costs, then Licensee shall continue to share the cost of such Clinical Trial until the effective date of termination.

Ongoing Clinical Trials. Unless expressly prohibited by any Regulatory Authority or Applicable Law, if any clinical studies involving Licensed Products sponsored by Anteris or its Affiliate or Sublicensee are being conducted as of the effective date of termination, at vTv’s written request in its sole discretion made within ​ days of the effective date of termination, Anteris shall, and shall cause its Affiliates and Sublicensees to, # wind down such clinical studies in accordance with Applicable Law, at ​, or (ii) (x) transfer sponsorship and control of such clinical studies to vTv and # continue to conduct such clinical studies for up to ​ months to enable such transfer to be completed without interruption of any such clinical study, in each case ((ii)(x) and (ii)(y)), at ​.

Ovid shall be obliged to bear the costs of the Ovid Ongoing Trials, if still ongoing; and

Ovid shall be obliged to bear the costs of the Ovid Ongoing Trials, if still ongoing; and

with respect to any ongoing clinical trials of the Compound conducted by EyePoint, # EyePoint shall wind down the conduct of such clinical trials as

Ongoing Clinical Trials. If at the time of such termination, any Clinical Trials for the Product are being conducted by or on behalf of Ji Xing, its Affiliates or sublicensees, then, at [[Cytokinetics:Organization]]’ election on a trial-by-trial basis: ​.

Wind-Down, Ongoing Clinical Trials and Continuous Supply. To the extent necessary, the Parties shall responsibly wind-down, in accordance with accepted pharmaceutical industry norms and ethical practices, any ongoing research and development programs under this Agreement. To clarify, any winding-down or changes to ongoing clinical trials due to termination of this Agreement must be performed according to Applicable Law and strictly comply with Good Clinical Practice (GCP), including but not limited to practices and ethical standards for continuous supply to such ongoing clinical trials.